Vaccine Development and Immunological Aspects of Ebola Virus Disease (EVD): An Update

Infectious diseases emergence and re-emergence over the last 50 years have increased. Ebola virus disease (EVD) has been a public health emergency of international concern, given its high risk of transmission, and its high case-fatality rate can reach over 40%. The EVD first emerged in 1976. Epidemics, particularly since 2014, have called for interventions, mainly those preventive and the specific aim of developing an effective vaccine. There are currently no licensed vaccines available to prevent EVD infections. However, since the discovery of EVD, different vaccine strategies, including monovalent, bivalent, and multivalent candidates, have been studied. In such a critical time, the health care community played an active role by fast-tracking an EVD vaccine, which was not available to stop the outbreak. The outbreak intensity could be reduced much more if VSV-ZEBOV had been assessed for safety after the initial stages of the pre-clinical study. Virus-Like Particles, Stomatitis


Background
Ebola Virus Disease (EVD) has been a public health emergency of international concern, given its high risk of transmission, and its high case-fatality rate can reach over 40%. Epidemics, particularly since 2014, have called for the need for interventions, mainly those preventive and the specific aim of developing an effective vaccine [1].

Ebola Virus Disease Vaccine
Infectious diseases emergence and re-emergence over the last 50 years have increased [1] and challenging public health at local, regional, national, and international levels. EVD first seems in 1976 [2], and till now, putting millions of lives at risk and killed across the world, including Africa. The current ongoing EVD outbreak in the Democratic Republic of Congo (DRC) accelerated the strategies and efforts to test vaccine candidates [3]. All these efforts aim to ensure public health safety and control further spreading and illnesses due to EVD. In the past, the vaccine development EVD has been hampered by lower priority in the public health sector, the need for high-level biocontainment, and a general lack of interest among pharmaceutical companies [1]. In West Africa, the response to highly pathogenic infectious diseases and rare emerging diseases has demonstrated that public health measures interfere with religion, politics, tradition, and human behavior [4].

Ebola Vaccine Development
There are currently no licensed vaccines available to prevent EVD infections [5]. However, since the discovery of EVD, different vaccine strategies, including monovalent, bivalent, and multivalent candidates, have been studied [6]. The thirteen Ebola Vaccine Candidates (EVC) are currently in different trial phases [5]; it may There is no definite evidence that antibody response is the human efficacy association of defense or surrogate endpoint, an immune response to vaccine correlated with vaccine-induced safety, and may vary depending on the vaccine platforms [7,9].
Previous studies focused on introducing a fast-acting immunization regimen with a protective response. However, after the supposition of the outbreak, the efficacy of vaccine-induced safety and potential benefits needs to be given more consideration of futures challenges [10]. Therefore, safety and immunogenicity accumulate under active clinical development for all candidate vaccines, measured after both priming and boosting, display detectable humoral, and cellular immune responses [11]. Though, there is limited followup time to document the maintenance of these immune responses.
Previous studies focused on introducing a fast-acting immunization regimen with a protective response. However, after the supposition of the outbreak, the efficacy of vaccine-induced safety and potential benefits needs to be given more consideration of futures challenges [10]. Therefore, safety and immunogenicity accumulate under active clinical development for all candidate vaccines, measured after both priming and boosting, display detectable humoral, and cellular immune responses [11]. Though, there is limited follow-up time to document the maintenance of these immune responses. The researchers demonstrated that the immune system reacts to the vaccination, and antibodies induce a wide range of different antibodies against the Ebola virus. Many of the antibodies investigated also exhibit highly neutralizing activity, which is generally essential for the protection against infections [12,5].
Moreover, immune correlates of protection from disease in humans remain unknown, therefore, to facilitate the licensing of drugs and biologics where the efficacy cannot be assessing the effectiveness of the candidate vaccine [8].

The Immune Response to EVD
The initial target of the Ebola Virus is myeloid cells, mainly  [15].

Antibody Responses to EVD
The previous studies showed unsatisfactory results of passive immunotherapy against EVD [16][17][18]. It showed that for protection, cellular immunity has more role compare with humoral immunity. The recent studies showed that specific antibodies for EVD glycoproteins could protect the form of immunotherapy or vaccine¬ induced antibody-responses, and in human, there is antibody production [19]. In 1995, the antibodies were used to treat the EVD by receiving a blood transfusion from recovering patients [20]. However, it is unclear that whether the patients were in the covering stage or the injected antibodies influence them. The current studies showed that the death of 31% of patients treated with the plasma of recovering patients by comparison with control patients of 38%. So, it showed the limited effect of antibody therapy [21].

Challenges and Future Considerations
When the West African EVD outbreak occurred, the global community was not ready to handle it. There was no vaccine, no drugs, limited diagnostic facilities, few medical teams, and no plan of action to deal with this outbreak. In such a critical time, the health care community played an active role by fast-tracking an EVD vaccine, which was not available to stop the epidemic. The intensity of the outbreak could be reduced if VSV-ZEBOV was assessed for safety after the initial stages of the pre-clinical study. For the travelers, WHO has not posed and ban to travel an endemic zone for any purpose [22]. Since Ebola outbreaks become usual for DRC, a comprehensive awareness program should be launched to educate the local communities to decrease future attacks. It will be possible to inform the residents about the signs and symptoms of Ebola and the mode of transmission. By emphasizing the importance of getting medical care and immediately reporting suspected individuals.
Local authorities should disseminate the health care messages in the local language to aware of the public on a large scale [23].

Author Contributions
All the authors potentially contributed to this manuscript.